Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.66 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999013 | 0.89 | TRPV1 (0.65) | TRPV1CYP3A4 | |
| SCHEMBL1000937 | 0.88 | TRPV1 (0.72) | TRPV1NAMPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL997622 | 0.86 | TRPV1 (0.88) | TRPV1NAMPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL998030 | 0.86 | TRPV1 (0.88) | TRPV1NAMPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL999203 | 0.84 | TRPV1 (0.88) | TRPV1NAMPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL998529 | 0.84 | TRPV1 (0.88) | TRPV1NAMPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL997416 | 0.84 | TRPV1 (0.71) | TRPV1NAMPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL997682 | 0.82 | TRPV1 (0.88) | TRPV1NAMPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL997954 | 0.81 | TRPV1 (0.83) | TRPV1NAMPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL999867 | 0.81 | TRPV1 (0.74) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1637521-B1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | TRPV1 2437/4885NAMPT 1807/4885MEN1 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.